| Subject | Contents |
| Definition | A group of inherited muscle problems characterized by muscle 'break down' following certain stimuli. Malignant hyperthermia can be brought on in susceptible people by anesthesia, extremes of exercise (particularly in hot conditions), fever or use of stimulant drugs. Problems associated with this condition result from 'over-excitable' muscle which contract uncontrollably, severe fever , abnormal heart rhythms and kidney failure. |
| Alternative Names | Hyperthermia - malignant; Hyperpyrexia - malignant |
| Causes, incidence, and risk factors | Malignant hyperthermia is inherited as an autosomal dominant trait (it requires only one affected parent for a child inherit the condition). It may be associated with muscular diseases such as muscular dystrophy and central core disease. Malignant hyperthermia is often noted for the first time during administration of anesthesia. The anesthetized patient rapidly develops a high fever and muscle rigidity '>muscle rigidity . During these episodes, muscle tissue is destroyed and break down products of muscle may damage the kidneys and cause acute renal failure . The urine may turn dark due to released muscle pigments (myoglobin) (see rhabdomyolysis ). Malignant hyperthermia can be fatal if not treated immediately. It can be prevented by administration of appropriate drugs before anesthesia. |
| Symptoms | rapid rise in temperature following administration of anesthesia muscle rigidity and stiffness following administration of anesthesia dark brown coloration to urine muscle ache without obvious exercise to explain sore muscles family history of malignant hyperthermia or unexplained death during anesthesia |
| Signs and tests | blood chemistry (see chem-20 ), increased blood levels of CK , potassium, uric acid, phosphate myoglobin in the urine is elevated biopsy - muscle using an in vitro contracture test, tissue can show abnormal results in response to certain drugs such as caffeine and halothane (an anesthetic) biopsy - muscle can show abnormal muscle, such as central cores, in some types genetic testing is available for multiple genes, the most common of which is the ryanodine receptor (RYR1) a research test that can show abnormal muscle function is phosphorus magnetic resonance spectroscopy |
| Treatment | The best medicine for this condition is prevention. If a general anesthetic is to be given, pretreatment with dantrolene sodium is recommended. If you have a family history of anesthesia-induced problems it is imperative to alert your surgeon and anesthesiologist. For an episode of malignant hyperthermia, antipyretics (fever-reducing medications such as acetaminophen) and a cooling blanket can help reduce acute fever . Intravenous and oral fluids as well as certain medications are essential for maintaining kidney function during an acute episode. |
| Support Groups | |
| Expectations (prognosis) | Episodes of the disorder can often be prevented. Repeated episodes or untreated episodes can cause kidney failure. Untreated episodes can be fatal but fortunately the use of the drug dantrolene has made fatal cases much less common. |
| Complications | rhabdomyolysisrenal failure death occasionally, myopathy (weak muscles) or muscular dystrophy |
| Calling your health care provider | If you know that you or a member of your family has had problems with general anesthesia (or if you know you have a family history of malignant hyperthermia) be sure to notify both the surgeon and the anesthesiologist before having any surgery. |
| Prevention | It is important to recognize susceptible patients before anesthesia. Clues may be obtained from the family history or previous episodes. Episodes of malignant hyperthermia may be prevented by giving dantrolene sodium before anesthesia. It is important to avoid stimulant drugs such as cocaine, amphetamine (speed) and ecstasy (an amphetamine derivative) as they may produce malignant hyperthermia-like problems in susceptible individuals. Genetic counseling is recommended for anyone with a family history of myopathy, muscular dystrophy or malignant hyperthermia. |
| | |